HemaTerra introduces scheduling system for blood clinics, hospitals

HemaTerra Technologies, Jacksonville, Florida-based providers of software to healthcare facilities handling blood and other biologic products, has launched HemaComply–Equipment Manager, a quality control scheduling system made especially for facilities that handle blood.

The maintenance of lab and medical equipment requires time to properly update calibration schedules for the large amount of equipment. The HemaComply-Equipment Manager takes over the roles of scheduling, documentation and review of preventative measures and supports.

By scheduling all equipment in a single system, the manager is able to keep equipment in check with specifications, therefore maintaining compliance throughout a facility. The system also includes multiple features such as order entry, inventory management and product quality control, giving clinicians the ability to identify issues within the systems at a faster pace.

"Our partners discussed their challenges with other equipment management systems and believe those challenges were amplified by using software that is antiquated in both design and direction. Also, that the software does not integrate with existing systems in the blood center's ecosystem,” said Todd Collins, president and CEO of HemaTerra Technologies. “What makes our product unique is that we are investing the time and resources to fully integrate this product with their usage of HemaConnect, HemaControl and HemaComply–QC. In other words, a piece of equipment taken out of service prompts an appropriate reaction within their donor recruitment, order entry, inventory management and QC areas."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.